Medication info
Danumet XR Extended Release Tablet 100/1000 mg

Danumet XR Extended Release Tablet 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
K.S. Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped, bilaterally convex extended-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300589 · Approved 2023.02.17 · Insurance code 059001170

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To preserve its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases of incomplete dissolution of this medicine and its passage in the stool have been reported. It is not known whether the material passed in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, a healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).

Ingredients

Manufacturer
K.S. Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication combines sitagliptin and metformin to help control blood sugar in patients with type 2 diabetes. It is effective in improving blood glucose levels in conjunction with dietary and exercise therapies. It supports patients in managing their blood sugar more stably and is used as an adjunct therapy for diabetes treatment.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To preserve its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases of incomplete dissolution of this medicine and its passage in the stool have been reported. It is not known whether the material passed in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, a healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).

Precautions

This medication contains both sitagliptin and metformin, and is used for blood sugar control in patients with type 2 diabetes. Firstly, when taking this medicine, attention should be paid to allergic reactions. Rarely, hypersensitivity reactions such as anaphylaxis, angioedema, and severe skin diseases may occur, and if such symptoms are suspected, the use of this medicine should be stopped immediately and a doctor should be consulted. Additionally, inflammation of the pancreas (pancreatitis) may occur, so symptoms like abdominal pain, nausea, or vomiting should be reported immediately to a physician. The metformin component can rarely cause a serious metabolic condition known as lactic acidosis; therefore, patients with impaired kidney function, liver disease, dehydration, severe infections, or heart failure should not take this medicine. Regular checks for normal kidney function should be conducted while taking this medication, and if kidney function decreases, the medication should be discontinued. Moreover, the intake of this medication should be temporarily halted before and after tests using iodine-containing contrast agents, and it may be resumed only after normal kidney function has been confirmed. Women who are pregnant or may become pregnant, and those who are nursing, should avoid taking this medication for safety. While using this medicine, irregular meals and vigorous exercise should be avoided, and alcohol consumption should also be limited. Hypoglycemic symptoms may occur, so monitoring blood sugar levels closely is necessary, especially when taking it with insulin or sulfonylureas. This medication may rarely cause severe joint pain or blistering skin symptoms, so if these symptoms occur, notify a doctor immediately. Lastly, it is important to undergo regular blood tests and kidney function tests while taking this medication, and to consult healthcare providers immediately if any unusual symptoms arise.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • severe hypoglycemia
  • elevated liver enzyme levels
  • acute renal failure
  • constipation
  • severe and debilitating arthralgia
  • blistering dermatitis herpetiformis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is important to maintain a normal room temperature, between 1 degree and 30 degrees Celsius, while storing the medication.

Appearance and packaging

Appearance

Bright blue, oval-shaped, bilaterally convex extended-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.